This study reviewed 28 cats with lymphoma who received lomustine and prednisolone; all tested negative for FeLV. It provides no observed outcomes for FeLV-positive cats with lymphoma. Many cases stopped contributing information to the survival analysis early on, limiting conclusions about how long the cats lived. The study also did not establish whether the lymphomas were T-cell or B-cell, so their responses could not be compared.
The retrospective clinical study published in Animals in 2026 (doi: 10.3390/ani16060989) included 28 cats with intermediate- to large-cell lymphoma who received lomustine and prednisolone as first-line chemotherapy. This was a small observational cohort with no reported concurrent control group. The three findings recorded in the knowledge object are classified as level C evidence.
All 28 cats tested negative for FeLV. The cohort therefore provides no directly observed outcomes for FeLV-positive cats with lymphoma. Negative test results do not establish that there had never been any historical viral involvement. The study did not investigate FeLV-driven oncogenesis, viral persistence, or leukemia. Immunophenotyping was not performed, preventing analysis of response differences between T-cell and B-cell lymphomas and limiting conclusions about lineage-specific outcomes.
The authors identify substantial early censoring and sparse later death events as limitations on survival interpretation. Failure to reach median survival does not demonstrate durable survival across the entire cohort. Broad grouping into gastrointestinal and non-gastrointestinal sites could have obscured anatomical differences. Weekly hematologic and biochemical monitoring was inconsistent, so transient abnormalities may have been missed. The authors also caution that nonsignificant prognostic associations do not establish a lack of clinical relevance and that the number of administrations largely reflected clinical response rather than serving as an independent predictor.
All 28 cats in this retrospective lymphoma cohort tested negative for FeLV. Immunophenotype was not determined, and response differences between T-cell and B-cell lymphomas could not be analyzed. Substantial early censoring limited survival interpretation. These findings constitute level C observational evidence.
This study does not establish outcomes for FeLV-positive cats with lymphoma or outcomes specific to T-cell or B-cell lineages. It also does not support concluding that survival was durable across the entire cohort, dismissing the clinical relevance of nonsignificant prognostic associations, or treating the number of administrations as an independent predictor. It did not investigate FeLV-driven oncogenesis, viral persistence, or leukemia; negative tests likewise do not establish the absence of historical viral involvement.
Excerpt verified in the source — verbatim, in the source's own language“Additionally, immunophenotypic classification of lymphoma cells into T-cell or B-cell lineages was not performed, precluding analysis of lineage-specific treatment responses.”
The findings cannot establish lineage-specific outcomes or explain differences in lymphoma biology through immunophenotype.
Excerpt verified in the source — verbatim, in the source's own language“In contrast, all 28 cats in our study tested negative for FeLV, and the alimentary form was predominant, accounting for 75.0% of the cases, whereas mediastinal lymphoma was observed in only 3.6% of cats.”
The cohort provides no directly observed outcomes for FeLV-positive lymphoma. Negative test results should not be expanded into a mechanistic claim about the absence of any historical viral involvement.
Excerpt verified in the source — verbatim, in the source's own language“Interpretation of survival outcomes in this study is limited by a substantial early-censoring pattern. Most censored cases occurred during the early follow-up period, whereas death events were relatively sparse and tended to occur later. This distribution of events may have precluded estimation of the MST using Kaplan–Meier analysis.”
Failure to reach median survival cannot be interpreted as proof of durable survival across the entire cohort.
AVA